Skip to main content

Incyte NIKTIMVO revenue

  • INCY · Nasdaq
  • Biotechnology
  • S&P 500
$120.97−0.60%Close 13 Nov 2026 · Market value $24.66B

NIKTIMVO revenue at Incyte came to $67.4M for the quarter to 30 Sep 2026, up 47.0% from a year earlier.

As Incyte reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$0Mar 2024$0Jun 2024$0Sep 2024$0Dec 2024$13.6MMar 2025$36.2MJun 2025$45.8MSep 2025$56.0MDec 2025$55.1MMar 2026$60.3MJun 2026$67.4MSep 2026
Incyte NIKTIMVO revenue, every reported period
Period endingNIKTIMVO revenueChange on a yearFiled
30 Sep 2026$67.4Mup 47.0%29 Oct 2026
30 Jun 2026$60.3Mup 66.8%28 Jul 2026
31 Mar 2026$55.1Mup 304.7%28 Apr 2026
31 Dec 2025$56.0M—10 Feb 2026
30 Sep 2025$45.8M—28 Oct 2025
30 Jun 2025$36.2M—29 Jul 2025
31 Mar 2025$13.6M—29 Apr 2025
31 Dec 2024$0—10 Feb 2025
30 Sep 2024$0—29 Oct 2024
30 Jun 2024$0—30 Jul 2024
31 Mar 2024$0—30 Apr 2024

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Incyte: Customer A (change on a year) · Customer B (change on a year) · Customer C (change on a year) · JAKAFI revenue · OPZELURA revenue · Product royalty revenues · JAKAVI revenue · ZYNYZ revenue · MINJUVI/MONJUVI revenue · Milestone and contract revenues · OLUMIANT revenue · ICLUSIG revenue · PEMAZYRE revenue · TABRECTA revenue · United States revenue · Europe revenue · financial statements

Every KPI and segment of INCY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.